利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.023 秒)

    GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
    4.
    发明申请
    GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES 失效
    GLUCAGON受体拮抗剂，制剂和治疗用途

    公开(公告)号：US20090156655A1

    公开(公告)日：2009-06-18

    申请号：US12093601

    申请日：2006-11-16

    申请人： Scott Eugene Conner ,  Philip Arthur Hipskind ,  Jianke Li ,  Guoxin Zhu

    发明人： Scott Eugene Conner ,  Philip Arthur Hipskind ,  Jianke Li ,  Guoxin Zhu

    IPC分类号： A61K31/41 ,  C07D257/06 ,  A61P3/10

    CPC分类号： C07D257/06 ,  C07D257/04

    摘要： The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

    摘要翻译： 本发明公开了具有胰高血糖素受体拮抗剂或反向激动剂活性的式（I）的新化合物或其药学上可接受的盐，以及制备这些化合物的方法。 在另一个实施方案中，本发明公开了包含式（I）化合物的药物组合物以及使用它们治疗糖尿病和其它与胰高血糖素相关的代谢紊乱等的方法。

    Peroxisome proliferator activated receptor modulators
    9.
    发明授权
    Peroxisome proliferator activated receptor modulators 失效
    过氧化物酶体增殖物激活受体调节剂

    公开(公告)号：US07259175B2

    公开(公告)日：2007-08-21

    申请号：US10505103

    申请日：2003-02-13

    申请人： Scott Eugene Conner ,  Nathan Bryan Mantlo ,  Guoxin Zhu

    发明人： Scott Eugene Conner ,  Nathan Bryan Mantlo ,  Guoxin Zhu

    IPC分类号： A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/4439 ,  C07D417/10 ,  C07D413/10

    CPC分类号： C07D413/04 ,  C07D263/32 ,  C07D277/24 ,  C07D277/26 ,  C07D413/10 ,  C07D417/04 ,  C07D417/10

    摘要： The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkenyl, substituted aryl(C0-C4)alkyl, substituted aryloxy(C0-C4)alkyl, substituted arylthio(C0-C4)alkyl, unsubstituted aryl(C0-C4)alkyl, unsubstituted aryloxy(C0-C4)alkyl, and unsubstituted arylthio(C0-C4)alkyl; (b) T1 is C or N; (c) Q is selected from the group consisting of O, a single bond, O(CH2)q and C; (d) q is 1 or 2; (e) W is selected from the group consisting of O, S, (CH2)rN(R20)(CH2)k, NHSO2, C(O)N(R20)(CH2)r, (CH2)rN(R20)C(O), and SO2; (f) X is CmH2m; (g) m is 0, 1 or 2; (h) A is an functional group selected from the group consisting of carboxyl, C1-C3 alkylnitrile, carboxamide, and (CH2)n COOR19; and (i) R19 is selected from the group consisting of hydrogen, optionally substituted C1-C4alkyl and optionally substituted arylmethyl

    摘要翻译： 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐，式I：其中：（a）R 5选自（C 1 -C 3） （C 1 -C 6）烷基，（C 1 -C 6 -C 6）链烯基，取代的芳基（C 0 -C 6 - 取代的芳氧基（C 0 -C 4 -C 4烷基）烷基，取代的芳硫基（C 0 -C 4 - 烷基，未取代的芳基（C 0 -C 4 -C 4）烷基，未取代的芳氧基（C 0 -C 4 - 烷基和未取代的芳硫基（C 0 -C 4 -C 4）烷基; （b）T1为C或N; （c）Q选自O，单键，O（CH 2 CH 2）q C和C; （d）q为1或2; （e）W选自O，S，（CH 2）n N（R 20）（CH 2 CH 2） C（O）N（R 20）（CH 2）n），（CH